These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20802826)

  • 21. Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model.
    Drusano GL; Myrick J; Maynard M; Nole J; Duncanson B; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Louie A
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
    de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
    Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
    Disratthakit A; Doi N
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2684-6. PubMed ID: 20368403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
    Alvirez-Freites EJ; Carter JL; Cynamon MH
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of drug combinations against dormant Mycobacterium tuberculosis.
    Filippini P; Iona E; Piccaro G; Peyron P; Neyrolles O; Fattorini L
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2712-5. PubMed ID: 20350948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
    Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J
    Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.
    Sala C; Dhar N; Hartkoorn RC; Zhang M; Ha YH; Schneider P; Cole ST
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4150-8. PubMed ID: 20679505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
    Nuermberger EL; Yoshimatsu T; Tyagi S; O'Brien RJ; Vernon AN; Chaisson RE; Bishai WR; Grosset JH
    Am J Respir Crit Care Med; 2004 Feb; 169(3):421-6. PubMed ID: 14578218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
    Cremades R; Rodríguez JC; García-Pachón E; Galiana A; Ruiz-García M; López P; Royo G
    J Antimicrob Chemother; 2011 Oct; 66(10):2281-3. PubMed ID: 21733966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis.
    Hu Y; Coates AR; Mitchison DA
    Int J Tuberc Lung Dis; 2008 Jan; 12(1):69-73. PubMed ID: 18173880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model.
    Ginsburg AS; Sun R; Calamita H; Scott CP; Bishai WR; Grosset JH
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3977-9. PubMed ID: 16127087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
    Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.
    Sirgel FA; Warren RM; Streicher EM; Victor TC; van Helden PD; Böttger EC
    J Antimicrob Chemother; 2012 May; 67(5):1088-93. PubMed ID: 22357804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains.
    Tortoli E; Dionisio D; Fabbri C
    J Chemother; 2004 Aug; 16(4):334-6. PubMed ID: 15332706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
    Srivastava S; Deshpande D; Magombedze G; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S359-S364. PubMed ID: 30496465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
    Drusano GL; Kim S; Almoslem M; Schmidt S; D'Argenio DZ; Myrick J; Duncanson B; Nole J; Brown D; Peloquin CA; Neely M; Yamada W; Louie A
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an
    de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system.
    Isaeva Y; Bukatina A; Krylova L; Nosova E; Makarova M; Moroz A
    J Antimicrob Chemother; 2013 Oct; 68(10):2274-81. PubMed ID: 23788475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
    Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.